NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge

Not Applicable

Not yet recruiting

Conditions: Diabetes

Interventions: Device: Continuous Glucose Monitor
Device: Blood Glucose Monitor

First Posted Date: 2022-09-21

Last Posted Date: 2024-10-30

Lead Sponsor: NYU Langone Health

Target Recruit Count: 120

Registration Number: NCT05548205

Locations: 🇺🇸
NYU Langone Hospital - Long Island, Mineola, New York, United States

Cognitive Markers in Prodromal MS

Not Applicable

Completed

Conditions: Multiple Sclerosis

Interventions: Device: Active tDCS

First Posted Date: 2022-09-16

Last Posted Date: 2024-08-05

Lead Sponsor: NYU Langone Health

Target Recruit Count: 60

Registration Number: NCT05543915

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Integrating Cultural Aspects Into Diabetes Education

Not Applicable

Recruiting

Conditions: PreDiabetes

Interventions: Behavioral: Diabetes Prevention Program (DPP)
Behavioral: Community-Supported Agriculture (CSA)

First Posted Date: 2022-08-09

Last Posted Date: 2024-07-16

Lead Sponsor: NYU Langone Health

Target Recruit Count: 150

Registration Number: NCT05492916

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer

Not Applicable

Recruiting

Conditions: Pancreatic Cancer

Interventions: Behavioral: HCP-Guided Exercise Training Program

First Posted Date: 2022-08-01

Last Posted Date: 2024-07-03

Lead Sponsor: NYU Langone Health

Target Recruit Count: 30

Registration Number: NCT05483075

Locations: 🇺🇸
NYU Langone Health Ambulatory Care Center, New York, New York, United States

Assessing Optimal XR-Buprenorphine Initiation Points in Jail

Phase 4

Withdrawn

Conditions: Opioid Use Disorder

Interventions: Drug: Extended-Release Buprenorphine Injection

First Posted Date: 2022-08-01

Last Posted Date: 2024-02-29

Lead Sponsor: NYU Langone Health

Registration Number: NCT05481112

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Enteral Feeding and Splanchnic NIRS Values in Infants With Neonatal Encephalopathy (NE)

Not Applicable

Completed

Conditions: Neonatal Encephalopathy

Interventions: Procedure: Enteral Feeding

First Posted Date: 2022-07-22

Last Posted Date: 2024-05-02

Lead Sponsor: NYU Langone Health

Target Recruit Count: 40

Registration Number: NCT05471336

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

RELAXaHEAD for Headache Patients (Phase II)

Not Applicable

Completed

Conditions: Migraine
Multiple Sclerosis
Headache
Insomnia

Interventions: Behavioral: Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)
Behavioral: Monitored Usual Care (MUC)

First Posted Date: 2022-07-20

Last Posted Date: 2024-01-10

Lead Sponsor: NYU Langone Health

Target Recruit Count: 48

Registration Number: NCT05466682

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Community-engaged Hypertension Prevention Program in Black Men

Not Applicable

Active, not recruiting

Conditions: Hypertension

Interventions: Behavioral: Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)
Behavioral: Barbershop-Based Facilitation (BF)

First Posted Date: 2022-07-07

Last Posted Date: 2024-06-26

Lead Sponsor: NYU Langone Health

Target Recruit Count: 430

Registration Number: NCT05447962

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2

Recruiting

Conditions: Melanoma
Unresectable Melanoma

Interventions: Drug: Sarilumab
Drug: Ipilimumab Injection
Drug: Nivolumab/Relatlimab

First Posted Date: 2022-06-22

Last Posted Date: 2024-08-23

Lead Sponsor: NYU Langone Health

Target Recruit Count: 69

Registration Number: NCT05428007

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
The Angeles Clinic at Cedars Sinai, Los Angeles, California, United States
🇺🇸
NYU Langone Health, New York, New York, United States

and more 1 locations

Life Study: Lifestyle Intervention in Fibroid Elimination

Not Applicable

Recruiting

Conditions: Uterine Fibroid

Interventions: Other: LIFE program

First Posted Date: 2022-06-13

Last Posted Date: 2024-04-24

Lead Sponsor: NYU Langone Health

Target Recruit Count: 100

Registration Number: NCT05416424

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy